




Are we ready for Personalized/Precision Medicine in CKD in Diabetes?



ckddiabetes.online

BARI, ITALY - 7th-8th MARCH, 2025

FACULTY

Con il patrocinio di



Con il patrocinio della

**SOCIETÀ
ITALIANA DI
DIABETOLOGIA**

PRESIDENTS

Paola Fioretto, Padova (Italy)

Loreto Gesualdo, Bari (Italy)

Francesco Giorgino, Bari (Italy)

SCIENTIFIC SECRETARIAT

Paola Pontrelli, Bari (Italy)



Giovambattista Capasso, Napoli (Italy)

Mark Cooper, Melbourne (Australia)

Salvatore De Cosmo, S. G. Rotondo - FG (Italy)

Luca De Nicola, Napoli (Italy)

Paola Fioretto, Padova (Italy)

Loreto Gesualdo, Bari (Italy)

Francesco Giorgino, Bari (Italy)

Maria Gomez, Malmo (Sweden)

Matthias Kretzler, Ann Arbor (USA)

Gaetano La Manna, Bologna (Italy)

Luigi Laviola, Bari (Italy)

Mario Luca Morieri, Padova (Italy)

Francesco Pesce, Roma (Italy)

Paola Pontrelli, Bari (Italy)

Michele Provenzano, Cosenza (Italy)

Peter Rossing, Copenhagen (Denmark)

Niina Sandholm-Laferre, Helsinki (Finland)

Anna Solini, Pisa (Italy)

Steven Sourbron, Sheffield (UK)

SCIENTIFIC RATIONALE

Chronic Kidney Disease (CKD) in patients with Type 2 diabetes represents a critical global health challenge, contributing significantly to increased morbidity and mortality. The interplay between CKD and Type 2 diabetes is a complex and multifaceted condition, shaped by a combination of genetic, environmental, and metabolic factors. This makes early diagnosis and effective management particularly challenging. However, the rise of personalized and precision medicine in recent years has opened promising avenues for tailoring treatments based on individual patient profiles, allowing for more accurate predictions of disease progression and therapeutic response.

This international meeting will bring together the leading experts from nephrology, diabetology, genomics, and omics technologies to share cutting-edge insights on the latest advancements in CKD and Type 2 diabetes care. The focus will be on how precision medicine can address unmet needs in the early diagnosis, classification, and treatment of CKD in patients with Type 2 diabetes. Key topics will include molecular phenotyping, genetic predispositions, advanced imaging techniques, and the potential of novel biomarkers and pharmacological interventions targeting specific pathways involved in CKD and Type 2 diabetes. A key highlight of the event will be the opportunity to review and discuss the latest scientific trials on CKD and Type 2 diabetes, many of which are nearing publication. These trials represent the forefront of research in the field, shedding light on emerging therapies and innovative approaches to disease management. By analyzing the results and implications of these studies, participants will gain a comprehensive understanding of current trends in CKD and Type 2 diabetes treatment and their potential impact on clinical practice.

Ultimately, this event aims to deepen understanding of how personalized and precision medicine can revolutionize the management of CKD in patients with Type 2 diabetes, equipping healthcare professionals with the knowledge and tools necessary to enhance patient outcomes. Through expert presentations, trial reviews, and interactive discussions, attendees will gain invaluable insights into the future of CKD and Type 2 diabetes treatment, fostering collaborations that may drive forward the next generation of research and clinical applications.

14:00 **Welcome and Introduction**
*Paola Fioretto, Loreto Gesualdo,
Francesco Giorgino*

**SESSION 1: EPIDEMIOLOGY,
DIAGNOSTICS AND ENDOPHENOTYPES**

Chairpersons: *Giovambattista
Capasso, Peter Rossing*

14:30 **Epidemiology and unmet needs
in early diagnosis**
Luca De Nicola

14:50 **Endophenotypes in CKD and
Type 2 diabetes**
Loreto Gesualdo

15:10 **New insights from imaging
for CKD and Type 2 diabetes**
Steven Sourbron

15:30 **Discussion and Q&A**

15:50 Coffee Break

**SESSION 2: GENETICS AND
MOLECULAR INSIGHTS**

Chairpersons: *Mark Cooper,
Francesco Pesce*

16:10 **Genetics of CKD and Type 2 diabetes**
Niina Sandholm-Laferre

16:30 **What we learned from transcriptomic
studies in CKD and Type 2 diabetes**
Paola Pontrelli

16:50 **Omics integration for precision
medicine in CKD and Type 2 diabetes**
Matthias Kretzler

17:10 **Biomarkers and the “BEAT DKD project”**
Maria Gomez

17:30 **Discussion and Q&A**

17:50 **Closing remarks from day 1**
*Paola Fioretto, Loreto Gesualdo,
Francesco Giorgino*

SATURDAY, MARCH 8th, 2025

09.00 **Recap and Introduction to day 2**
*Paola Fioretto, Loreto Gesualdo,
Francesco Giorgino*

SESSION 3: THERAPEUTIC ADVANCES IN CKD AND TYPE 2 DIABETES

Chairpersons: *Salvatore De Cosmo,
Hiddo Lambers Heerspink*

09.10 **SGLT2 inhibitors in CKD and
Type 2 diabetes management:
evidence and mechanism**
Paola Fioretto

09.30 **GLP-1 RA in CKD and Type 2
diabetes management: evidence
and mechanism**
Mark Cooper

09.50 **MRAS in CKD and Type 2
diabetes management:
evidence and mechanism**
Peter Rossing

10.10 **Roundtable discussion and Q&A**
Discussants: *Gaetano La Manna,
Anna Solini*

11:00 Coffee Break

SESSION 4: FUTURE DIRECTIONS IN CKD AND TYPE 2 DIABETES MANAGEMENT

Chairpersons: *Matthias Kretzler,
Luigi Laviola*

11:20 **Personalized treatment in CKD:
Insights from PRIME-CKD**
Hiddo Lambers Heerspink

11:40 **Novel concepts in gene therapy
for CKD**
Tobias Huber

12:00 **Emerging approaches in CKD
and Type 2 diabetes management**
Francesco Giorgino

12:20 **Roundtable discussion and Q&A**
Discussants: *Mario Luca Morieri,
Michele Provenzano*

13:15 **Closing Remarks and Summary**
*Paola Fioretto, Loreto Gesualdo,
Francesco Giorgino*

GENERAL INFORMATION

CONGRESS VENUE

The Nicolaus Hotel Bari

Via Cardinale Agostino Ciasca, 27
70124 Bari • Italy • Tel. +39 080 568 2111

REGISTRATIONS

Free Registration at:

<https://online.aristea.com/event/dkd25>

C.M.E. Continuing Medical Education

The Congress has been included by Aristea Education (Provider ID 500) within the framework of the National CME Program. Target audience: Cardiology; Endocrinology; General Surgery, Geriatrics; Metabolic Diseases and Diabetology; Internal Medicine; Nephrology; Nutrition Science and Dietetics. The certification of credits is subject to 100% participation in the entire training program and to learning verification and it will be available

at www.aristeaeducation.it no earlier than 60 days from the closing date of the event. Grants 7 C.M.E. credits

C.M.E. PROVIDER

 **aristea education**

Via XII Ottobre, 1 - Piano 6
16121 Genova • Italy
Tel. +39 010 7766457
E-mail info@aristeaeducation.it
Web www.aristeaeducation.it

ORGANIZING SECRETARIAT

 **aristea**

Via Roma, 10 • 16121 Genova • Italy
Tel. +39 010 553591
E-mail genova@aristea.com
Web www.aristea.com

Unconditionally supported by:

AstraZeneca 



 **Boehringer
Ingelheim**

Lilly


novo nordisk®